Molly Lutz, APRN
Psychiatric/Mental Health · Crestview Hills, KYNPI 1821588476
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $58,225 of the $70,597 with a category attached, or 82.5%. AbbVie accounts for 91.7% of it on its own, with 20 other manufacturers making up the rest. Among psychiatric/mental health clinicians in KY with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 538 payments — averaging $131.22 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$65K
- Otsuka America Pharmaceutical, Inc.$910
- Supernus Pharmaceuticals, Inc.$622
- Teva Pharmaceuticals USA, Inc.$613
- Axsome Therapeutics, Inc.$563
- Alkermes, Inc.$471
- plus $3K from 15 others
What the payments were for
- Speaking & faculty fees$58,22582%
- Travel & lodging$1,5102%
- Food & beverage$10,85515%
- Education$80%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 252 | $64,721 |
| Otsuka America Pharmaceutical, Inc. | 44 | $910 |
| Supernus Pharmaceuticals, Inc. | 20 | $622 |
| Teva Pharmaceuticals USA, Inc. | 24 | $613 |
| Axsome Therapeutics, Inc. | 25 | $563 |
| Alkermes, Inc. | 18 | $471 |
| Lundbeck LLC | 26 | $450 |
| Neurocrine Biosciences, Inc. | 30 | $436 |
| Takeda Pharmaceuticals U.S.A., Inc. | 22 | $351 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 20 | $320 |
| Corium, LLC | 14 | $274 |
| Johnson & Johnson | 10 | $264 |
| Sunovion Pharmaceuticals Inc. | 12 | $201 |
| Vanda Pharmaceuticals Inc. | 7 | $152 |
| Noven Therapeutics, LLC | 3 | $50 |
| Almatica Pharma LLC | 2 | $46 |
| Avanir Pharmaceuticals, Inc. | 2 | $43 |
| E.r. Squibb & Sons, L.L.C. | 2 | $34 |
| Bausch Health US, LLC | 2 | $31 |
| Ironshore Pharmaceuticals Inc. | 2 | $29 |
| Alfasigma USA, Inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- VRAYLAR$61,082
- ARISTADA$469
- QELBREE$393
- Auvelity$120
- AUSTEDO$118
- ARISTADA INITIO$117
- REXULTI$107
- SPRAVATO$106
- Austedo XR$101
How this compares
$70,597 in reported general payments places this provider in the 95th percentile of 946 psychiatric/mental health providers in Kentucky.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| VraylarCariprazine Hcl | 32 | $45,499 |
| TrintellixVortioxetine Hydrobromide | 22 | $10,994 |
| Aripiprazole | 115 | $10,394 |
| Lurasidone Hcl | 26 | $3,893 |
| Quetiapine Fumarate | 145 | $2,976 |
| Duloxetine Hcl | 166 | $2,820 |
| Lisdexamfetamine Dimesylate | 13 | $2,762 |
| Atomoxetine Hcl | 26 | $2,586 |
| Ziprasidone Hcl | 26 | $2,306 |
| Trazodone Hcl | 218 | $2,149 |
| Bupropion XlBupropion Hcl | 143 | $1,834 |
| Buspirone Hcl | 175 | $1,385 |
| Venlafaxine Hcl ErVenlafaxine Hcl | 55 | $1,351 |
| Hydroxyzine Hcl | 88 | $1,342 |
| Clonazepam | 155 | $1,324 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieVraylar | $64,721 | $45,49932 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Trintellix | $351 | $10,99422 claims |
| Almatica Pharma LLCSertraline Hcl | $46 | $54364 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 946 psychiatric/mental health providers in Kentucky.
Other psychiatric/mental health in Crestview Hills
- Jennifer SampangCrestview Hills$322K
- Sithandiwe MamutseCrestview Hills$13K
- Brent PlummerCrestview Hills$10K
- Amerika HullCrestview Hills$8K
- Theresa WattsAshland$645K
- Rachel ColeHopkinsville$503K
- Denise de AngelisLouisville$384K
- Jeremy FisherSouth Shore$197K
- Jessica EstesLewisport$175K
- Christopher MulloneyNancy$95K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.